New combo attack on tough liver cancer
NCT ID NCT06882876
Summary
This early-stage study is testing the safety of a three-part treatment for liver cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (JS014 and Toripalimab) with a standard procedure that blocks the tumor's blood supply (TACE). The goal is to see if this combination is safe and can help control the cancer in about 20 adults with advanced liver cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiangya Hospital
Changsha, Hunan, China
Conditions
Explore the condition pages connected to this study.